Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The potential of the TSAFinder tool in hematological oncology

Travis Johnson • 26 Aug 2022
IMS 2022
General CAR-T

Travis Johnson, PhD, MS, Indiana University School of Medicine, Indianapolis, IN, comments on the potential of TSAFinder, a tool designed to detect tumor-specific antigens, in finding novel antigens for CAR-T therapies to treat hematological malignancies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Travis Johnson

1:11
Single-cell multiomics analysis and the role of PHF19 expression in high-risk multiple myeloma
Travis Johnson • 26 Aug 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals